Standard Tigecycline Dosing Basics
Tigecycline, an IV glycylcycline antibiotic for complicated infections, uses fixed dosing regardless of age or renal function: 100 mg loading dose, then 50 mg every 12 hours. No adjustments are needed for renal impairment, including end-stage disease or dialysis, as <20% of the drug is excreted unchanged by kidneys.[1]
Why Renal Function Doesn't Change Dosing
Tigecycline primarily undergoes biliary/fecal elimination (59% in feces). Hepatic metabolism and minimal renal clearance mean creatinine clearance (CrCl) or eGFR has little effect on exposure. FDA and EMA labels confirm no dose changes for CrCl down to <10 mL/min or hemodialysis.[1][2]
Considerations for Elderly Patients
Elderly patients often have reduced renal function (e.g., CrCl <60 mL/min common due to age-related decline), but tigecycline dosing stays the same. Monitor for:
- Increased half-life (up to 3x longer in severe impairment), though AUC rises minimally (~20-30%).
- Higher infection risk from comorbidities like frailty or polypharmacy, not directly tied to tigecycline pharmacokinetics.
Cockcroft-Gault or MDRD formulas overestimate CrCl in elderly; actual function may be lower, but this doesn't alter tigecycline regimen.[3]
Dialysis and Elderly Overlap
Tigecycline is not dialyzable (large molecular weight, high protein binding). No supplemental post-dialysis dose needed, relevant for elderly on chronic dialysis for comorbidities like diabetes.[1]
Potential Risks and Monitoring in Elderly with Poor Renal Function
While dosing is unchanged:
- Elevated trough levels may heighten nausea, vomiting, or superinfection risks (e.g., C. difficile), more pronounced in elderly.
- Mortality signal in ventilator-associated pneumonia trials (not renal-specific) warrants caution; use only when alternatives fail.
Check liver function instead, as hepatic impairment requires adjustment. Elderly: baseline renal/hepatic labs, daily monitoring.[2][4]
How It Compares to Other Antibiotics
Unlike vancomycin or aminoglycosides (renal-adjusted in elderly), tigecycline avoids TDM or CrCl-based tweaks. Alternatives like meropenem need reductions if CrCl <50 mL/min.[3]
Sources
[1]: FDA Tigecycline Label
[2]: EMA Tygacil Summary
[3]: Clinical Pharmacology Review - Tigecycline
[4]: IDSA Guidelines - HAP/VAP